115548-15-7

Basic information

• Product Name: (R)-4-(3-AMINO-BUTYL)-PHENOL
• Synonyms: (R)-4-(3-AMINO-BUTYL)-PHENOL;(R)-1-METHYL-3-(P-HYDROXY-PHENYL)-PROPYLAMINE;(R)-2-AMINO-4-(4-HYDROXYPHENYL)BUTANE
• CAS NO: 115548-15-7
• Molecular Formula: C10H15NO
• Molecular Weight: 165.23
• Product Categories: pharmacetical
• Mol File: 115548-15-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 295.3 °C at 760 mmHg
• Flash Point: 132.4 °C
• Appearance: /
• Density: 1.047 g/cm³
• Vapor Pressure: 0.000874mmHg at 25°C
• Refractive Index: 1.552
• PKA: 10.02±0.15(Predicted)
• CAS DataBase Reference: (R)-4-(3-AMINO-BUTYL)-PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-(3-AMINO-BUTYL)-PHENOL(115548-15-7)
• EPA Substance Registry System: (R)-4-(3-AMINO-BUTYL)-PHENOL(115548-15-7)

Safety Data

• Hazardous Substances Data: 115548-15-7(Hazardous Substances Data)

Usage

General Description

(R)-4-(3-Amino-butyl)-phenol is a chemical compound with the molecular formula C10H15NO. It is a phenolic compound with an amino group and a butyl side chain attached to the aromatic ring. This chemical has potential applications in pharmaceuticals and industrial products due to its unique structure and properties. It may also have biological and medicinal uses, although further research is needed to fully understand its potential. Overall, (R)-4-(3-Amino-butyl)-phenol is a promising molecule with diverse potential applications in various fields.

InChI:InChI=1/C10H15NO/c1-8(11)2-3-9-4-6-10(12)7-5-9/h4-8,12H,2-3,11H2,1H3/t8-/m1/s1

Upstream product

• 51062-15-8 (+)-(R)-1-Methyl-3-(4-methoxyphenyl)-1-propylamine 
• 1222558-29-3 [((E)-4-(4-methoxyphenyl)but-3-en-2-ylidene)amino]hydroxide 
• 5471-51-2 4-(4-hydroxyphenyl)-2-oxobutane 
• 22214-30-8 4-(4'-hydroxyphenyl)but-3-en-2-one 
• 123-08-0 4-hydroxy-benzaldehyde 

Relevant articles and documents

8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study

β2-Agonists that bind to plasmalemmal β2-adrenoceptors causing cAMP accumulation are widely used as bronchodilators in chronic respiratory diseases. Here, we designed and synthesized a group of 8-hydroxyquinolin-2(1H)-one analogues and studied their β2-agonistic activities with a cellular cAMP assay. Compounds B05 and C08 were identified as potent (EC50 2-agonists among the compounds tested. They behaved as partial β2-agonists in non-overexpressed HEK293 cells, and possessed rapid smooth muscle relaxant actions and long duration of action in isolated guinea pig tracheal strip preparations. In summary, B05 and C08 are β2-agonists with potential applicability in chronic respiratory diseases.

MOF-derived cobalt nanoparticles catalyze a general synthesis of amines

The development of base metal catalysts for the synthesis of pharmaceutically relevant compounds remains an important goal of chemical research. Here, we report that cobalt nanoparticles encapsulated by a graphitic shell are broadly effective reductive amination catalysts. Their convenient and practical preparation entailed template assembly of cobaltdiamine- dicarboxylic acid metal organic frameworks on carbon and subsequent pyrolysis under inert atmosphere.The resulting stable and reusable catalysts were active for synthesis of primary, secondary, tertiary, and N-methylamines (more than 140 examples).The reaction couples easily accessible carbonyl compounds (aldehydes and ketones) with ammonia, amines, or nitro compounds, and molecular hydrogen under industrially viable and scalable conditions, offering cost-effective access to numerous amines, amino acid derivatives, and more complex drug targets.

Derivatives related to betaxolol with α- and β-adrenergic activities

The paper describes the synthesis and the pharmacological evaluation of some derivatives of betaxolol, all with an N-aralkylamine instead of the tertiobutylamine. These compounds have been tested for β1-adrenergic receptor antagonism on guinea pig atria, β2-adrenergic receptor antagonism on guinea pig trachea and α-adrenergic blocking activity on rat aorta. Compound U12 with a marked α-blocking activity and compound R8 with a β1/α ratio = 1 were selected for a haemodynamic study in the dog. The decrease in cardiac work and the diminution of total peripheral resistance exhibited by U12 are consistent with a dual α/β-blocking agent. Finally, structure-activity relationships are discussed.